The Impact of Disease Activity Criteria on Extending Injection Intervals in Real-World Patients with Neovascular Age-Related Macular Degeneration
Authors:
- Bhairavi BhatiaBBBhairavi Bhatia
- Sing Yue SimSSSing Yue Sim
- Evangelia ChalkiadakiECEvangelia Chalkiadaki
- Georgios KoutsocherasGKGeorgios Koutsocheras
- Luke NicholsonLNLuke Nicholson
- Senthil SelvamSSSenthil Selvam
- Sobha SivaprasadSSSobha Sivaprasad
- Josef HuemerJHJosef Huemer
- Pearse A. KeanePKPearse A. Keane
- Robin HamiltonRHRobin Hamilton
- Praveen J. PatelPPPraveen J. Patel
Open Access
- 27 February 2025
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 14 (4) , 773-786
Abstract
Introduction In clinical practice, intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection intervals for patients with neovascular age-related macular degeneration (nAMD) are based on disease activity, with active or recurrent disease requiring more frequent injections. Injection interval modification criteria differ from those used in clinical trials, thereby potentially affecting treatment outcomes. This analysis evaluated the potential impact of applying disease activity criteria from recent clinical trials (TENAYA/LUCERNE; HAWK/HARRIER; PULSAR) on the decision to extend injection intervals in real-world patients commenced on faricimab after the loading phase of treatment and at 12 months. Methods Data were analysed from 105 treatment-naïve patients with nAMD who received anti-VEGF injections at Moorfields Eye Hospital. Disease activity criteria from TENAYA/LUCERNE, HAWK/HARRIER and PULSAR clinical trials were applied to determine the hypothetical impact on the decision to modify injection intervals at week 12 (fourth injection) and 12-month real-world clinic visits. Results At 12 weeks, 79% of patients had injection intervals extended in clinical practice compared to 80% when applying hypothetical TENAYA/LUCERNE disease activity criteria; 77% using HAWK/HARRIER and 96% using PULSAR. There was agreement between clinical practice and all clinical trials in 60% of eyes, and no agreement in 13%. At 12 months, fewer patients were inactive, with 55% of eyes quiescent in clinical practice, 58% when applying TENAYA/LUCERNE criteria and 67% using HAWK/HARRIER. Application of PULSAR disease activity criteria showed 96% of patients were classed as inactive. 34% of eyes showed agreement in disease activity status between clinical practice and all clinical trials at 12 months, with no agreement in 20%. Conclusions Applying disease activity criteria from clinical trials to clinical practice can have a significant impact on hypothetical anti-VEGF injection intervals. Consideration should be paid to which criteria are used in real-world practice to help achieve treatment burden reductions and optimal treatment outcomes seen in clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Impact of macular fluid volume fluctuations on visual acuity during anti-VEGF therapy in eyes with nAMDEye, 2021
- HAWK and HARRIEROphthalmology, 2021
- Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degenerationEye, 2020
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular DegenerationOphthalmology, 2020
- Biomarkers of optical coherence tomography in evaluating the treatment outcomes of neovascular age-related macular degeneration: a real-world studyScientific Reports, 2019
- Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysisThe Lancet Global Health, 2017
- Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal FluidOphthalmology, 2016
- Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW TrialsOphthalmology, 2016
- Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments TrialsOphthalmology, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012